<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194284</url>
  </required_header>
  <id_info>
    <org_study_id>C23003</org_study_id>
    <secondary_id>2009-017204-89</secondary_id>
    <nct_id>NCT01194284</nct_id>
  </id_info>
  <brief_title>Surveillance Study of Patients With Newly Diagnosed Osteosarcoma</brief_title>
  <official_title>Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational safety surveillance study designed to prospectively assess
      patients with high-grade osteosarcoma who are candidates for treatment with mifamurtide
      within the context of prevailing standard oncology practice
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Regulatory agency commitment fulfilled.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term safety profile of mifamurtide during treatment (mifamurtide in combination with chemotherapy)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Adverse events of special interest (AESIs), including important identified and potential risks
The frequency and pattern of mifamurtide-related infusion adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The long-term safety profile of mifamurtide during and following treatment (mifamurtide in combination with chemotherapy)</measure>
    <time_frame>Up to 5 years from the last dose of mifamurtide or until death</time_frame>
    <description>Assessment of AESIs, consisting of important identified and potential risks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 5 years from the last dose of mifamurtide or until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years from the last dose of mifamurtide or until death</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>High-grade osteosarcoma patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifamurtide</intervention_name>
    <description>Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.</description>
    <arm_group_label>High-grade osteosarcoma patients</arm_group_label>
    <other_name>MEPACT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of patients with high-grade osteosarcoma who are candidates
        for treatment with mifamurtide within the context of prevailing standard oncology practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Male or female aged 2 to 40 years

          -  Confirmed pathological diagnosis of newly-diagnosed, nonmetastatic, resectable,
             primary, high-grade osteosarcoma

          -  Have completed definitive surgery (or other local ablation technique)

          -  Have a treatment regimen that includes mifamurtide and a minimum of 2 recognized
             chemotherapy agents in the treatment of osteosarcoma (cisplatin, doxorubicin,
             high-dose methotrexate or ifosfamide)

          -  Organ function deemed satisfactory to receive planned chemotherapy containing at
             minimum 2 of the recognized chemotherapy agents in the treatment of osteosarcoma

          -  Voluntary Written Consent

        Exclusion Criteria

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Female patients who are lactating and breastfeeding or have a positive serum pregnancy
             test during the screening period

          -  History of pericarditis or pleuritis

          -  Have low-grade osteosarcoma or parosteal or periosteal sarcoma

          -  Have osteosarcoma associated with Paget's disease

          -  Current treatment with any anticancer investigational products at the time of
             enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Wien Universitätsklinik für Innere Medizin I Klinische Abteilung für Onkologie</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifamurtide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

